Rocket Pharmaceuticals Inc
NASDAQ:RCKT

Watchlist Manager
Rocket Pharmaceuticals Inc Logo
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Watchlist
Price: 3.28 USD 4.79%
Market Cap: 353.4m USD

Operating Margin
Rocket Pharmaceuticals Inc

0%
Current
0%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-270.2m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
345.3m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
329.9B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
163B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
137.6B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.5B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
127.8B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.2B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Rocket Pharmaceuticals Inc
Glance View

Market Cap
350.2m USD
Industry
Biotechnology

Rocket Pharmaceuticals Inc. is an intriguing player in the biotechnology sector, renowned for its ambition to address rare and devastating genetic diseases. At its core, Rocket is dedicated to the development of gene therapies—a cutting-edge field where genetic material is introduced into a patient's cells to rectify or replace malfunctioning genes. Rocket's focus primarily revolves around ex vivo lentiviral vector treatments and in vivo adeno-associated viral vector-based therapies. These methods involve either modifying cells outside the body (ex vivo) and reintroducing them or delivering therapeutic DNA directly into cells within the body (in vivo). This innovative approach aims to provide lasting relief or even potential cures for some of the most stubborn genetic afflictions. The company's revenue model is typical of biotechnology firms at this stage of development. Rocket draws financial sustenance primarily through strategic partnerships, licensing agreements, and funding from investors who share its vision of a healthier future. Essentially, the promise that their pipeline therapies hold for addressing high unmet medical needs is leveraged to secure funding and collaborations with larger pharmaceutical entities. Additionally, as their candidates advance through clinical trials towards potential commercialization, Rocket anticipates future revenue streams from product sales. Thus, the company resides in a dynamic phase where scientific advancement and strategic financial engineering walk hand-in-hand, reflecting a classic model of a biotech innovator pursuing long-term value creation.

RCKT Intrinsic Value
2.24 USD
Overvaluation 32%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-270.2m
/
Revenue
0
What is the Operating Margin of Rocket Pharmaceuticals Inc?

Based on Rocket Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top